Эффективность, безопасность и риск селекции резистентной микрофлоры при лечении тяжелых инфекций в стационаре препаратом с действующими веществами цефепим + [сульбактам] по сравнению с препаратами карбапенемов

[1]  H. Giamarellou,et al.  Carbapenem-Sparing Strategies for ESBL Producers: When and How , 2020, Antibiotics.

[2]  D. Wareham,et al.  Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections. , 2019, The Journal of antimicrobial chemotherapy.

[3]  T. Lupia,et al.  Carbapenem-sparing strategy: carbapenemase, treatment, and stewardship. , 2019, Current opinion in infectious diseases.

[4]  S. Besset,et al.  Use of non-carbapenem antibiotics to treat severe extended-spectrum β-lactamase-producing Enterobacteriaceae infections in intensive care unit patients. , 2019, International journal of antimicrobial agents.

[5]  L. Visser,et al.  Using local clinical and microbiological data to develop an institution specific carbapenem-sparing strategy in sepsis: a nested case-control study , 2019, Antimicrobial Resistance & Infection Control.

[6]  J. Al-Tawfiq,et al.  Impact of carbapenem versus non-carbapenem treatment on the rates of superinfection: A meta-analysis of randomized controlled trials. , 2018, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[7]  P. Christos,et al.  Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis. , 2018, International journal of antimicrobial agents.

[8]  K. Peck,et al.  Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study , 2018, European Journal of Clinical Microbiology & Infectious Diseases.

[9]  C. Tebé,et al.  Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia , 2017, Antimicrobial Agents and Chemotherapy.

[10]  Robert A. Weinstein,et al.  The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace , 2017, The Journal of infectious diseases.

[11]  M. Bassetti,et al.  Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections , 2017, Expert review of anti-infective therapy.

[12]  U. Sekar,et al.  Carbapenemase-producing Enterobacteriaceae: Risk factors for infection and impact of resistance on outcomes , 2017, International journal of applied & basic medical research.

[13]  M. Dizbay,et al.  Treatment efficacy and superinfection rates in complicated urinarytract infections treated with ertapenem or piperacillin tazobactam. , 2016, Turkish journal of medical sciences.

[14]  D. Paterson,et al.  Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae , 2015, Antimicrobial Resistance and Infection Control.

[15]  W. Ko,et al.  Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  K. Kaye,et al.  Impact of Cefepime Therapy on Mortality among Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli , 2012, Antimicrobial Agents and Chemotherapy.

[17]  Zhaoxia Li,et al.  In vitro activity of cefepime combined with sulbactam against clinical isolates of carbapenem-resistant Acinetobacter spp. , 2006, International journal of antimicrobial agents.

[18]  H. Goossens,et al.  High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[19]  H. Goossens,et al.  Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  M. Schaller,et al.  Cefepime versus Imipenem-Cilastatin for Treatment of Nosocomial Pneumonia in Intensive Care Unit Patients: a Multicenter, Evaluator-Blind, Prospective, Randomized Study , 2003, Antimicrobial Agents and Chemotherapy.

[21]  R. Courcol,et al.  Bactericidal activity of three β-lactams alone or in combination with a β-lactamase inhibitor and two aminoglycosides against Klebsiella pneumoniae harboring extended-spectrum β-lactamases , 1998 .

[22]  R A Weinstein,et al.  Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. , 1996, The Journal of infectious diseases.